ReviewFEBS letters2026
Phosphatidylinositol 4-kinase as a target of pathogens-friend or foe?
Review in FEBS letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Phosphoinositides and inositol phosphates-functions and cellular dynamics.FEBS letters · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Phosphatidylinositol 4-kinases (PI4Ks) are pivotal enzymes responsible for the generation of phosphatidylinositol 4-phosphate (PI4P), a key precursor involved in various cellular signalling pathways that regulate vesicular trafficking, Golgi maintenance and intracellular communication. Conserved across eukaryotic species, PI4Ks exist in distinct isoforms with specific localisations and functions, ranging from plasma membrane dynamics to endosomal trafficking and autophagy regulation. Notably, numerous pathogens, including viruses, bacteria and parasites, have evolved mechanisms to hijack host PI4Ks, thereby facilitating intracellular replication and survival. For example, RNA viruses within the Flaviviridae and Coronaviridae families recruit PI4Ks to remodel host membranes for the assembly of replication complexes. Similarly, intracellular bacteria such as Salmonella and Legionella manipulate PI4P-enriched compartments to evade host defences and promote replication. Due to their central roles in both normal cellular physiology and infection, PI4Ks have emerged as promising therapeutic targets. A variety of inhibitors, including ATP-competitive compounds, have been developed and evaluated for their antiviral, antibacterial and antiparasitic potential. Nevertheless, challenges related to selectivity and toxicity remain. Recent advances include the identification of inhibitors effective against Plasmodium species and the development of compounds targeting PI4KIIIβ in infections with viruses such as hepatitis C and coronaviruses. This review highlights the dual role of PI4Ks as essential cellular regulators and exploitable pathogen cofactors, underscoring their potential as drug targets. Continued investigation into the structure, function and inhibition of PI4Ks may enable the development of selective therapeutic strategies for infectious diseases while minimising off-target effects on host cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.